Other Corporate Information

• 7 Dec, 2023
  Första patienten doserad i Spago Nanomedicals kliniska fas I/IIa-studie inom Tumorad®-programmet
• 7 Dec, 2023
  First patient dosed in Spago Nanomedical’s clinical phase I/IIa study within the Tumorad® program
• 23 Nov, 2023
  Sista dagen i teckningsperioden i Spago Nanomedicals företrädesemission
• 23 Nov, 2023
  Last day of the subscription period in Spago Nanomedical’s rights issue
• 9 Nov, 2023
  The subscription period in Spago Nanomedical’s rights issue begins today
• 9 Nov, 2023
  Idag börjar teckningsperioden i Spago Nanomedicals företrädesemission
• 24 Oct, 2023
  Spago Nanomedical ansöker om utökat patentskydd för Tumorad®
• 24 Oct, 2023
  Spago Nanomedical applies for extended patent protection for Tumorad®
• 19 Oct, 2023
  Spago Nanomedical får klartecken att starta klinisk fas I/IIa-studie med Tumorad® i Australien
• 19 Oct, 2023
  Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia